Segment, Geographic and Other Revenue Information - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended
		Apr. 02, 2017	Apr. 03, 2016
Segment Reporting Information [Line Items]
Certain legal matters, net	[1]	$ 8	$ 274
Impairment on remeasurement of HIS net assets	[2],[3]	(37)	0
Business and legal entity alignment costs	[4]	21	51
Certain asset impairments	[5]	12	131
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Cost reduction and productivity initiatives excluding acquisition related costs		78	137
Certain legal matters, net		8	286
Business and legal entity alignment costs		21	51
Certain asset impairments			131
Other nonoperating charges		13	34
Adjustment [Member] | Corporate [Member]
Segment Reporting Information [Line Items]
Costs and expenses			27
HIS [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Impairment on remeasurement of HIS net assets		$ 37
GPD [Member] | Adjustment [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Costs and expenses			76
WRD and GPD [Member] | Adjustment [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Costs and expenses			(27)
Innovative Health Segment [Member] | Innovative Health Business [Member] | Adjustment [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Costs and expenses			$ (76)

[1] In the first quarter of 2016, primarily includes an accrual for a then unresolved legal matter and a settlement related to a patent matter.

[2] Amounts may not add due to rounding.

[3] In the first quarter of 2017, represents an incremental charge to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical.

[4] Represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.

[5] In the first quarter of 2016, primarily includes an impairment loss of $81 million related to Pfizer’s 49%-owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer’s 40%-owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2D.